Trial watch: TLR3 agonists in cancer therapy

ABSTRACT Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in endosomes. On activation, TLR3 initiates a signal transduction pathway that culminates with the secretion of pro-inflammatory cytokines including type I interferon (IFN). The latter is essential not only for innate immune responses to infection but also for the initiation of antigen-specific immunity against viruses and malignant cells. These aspects of TLR3 biology have supported the development of various agonists for use as stand-alone agents or combined with other therapeutic modalities in cancer patients. Here, we review recent preclinical and clinical advances in the development of TLR3 agonists for oncological disorders. Abbreviations cDC, conventional dendritic cell; CMT, cytokine modulating treatment; CRC, colorectal carcinoma; CTL, cytotoxic T lymphocyte; DC, dendritic cell; dsRNA, double-stranded RNA; FLT3LG, fms-related receptor tyrosine kinase 3 ligand; HNSCC, head and neck squamous cell carcinoma; IFN, interferon; IL, interleukin; ISV, in situ vaccine; MUC1, mucin 1, cell surface associated; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; polyA:U, polyadenylic:polyuridylic acid; polyI:C, polyriboinosinic:polyribocytidylic acid; TLR, Toll-like receptor

[1]  H. Yin,et al.  Small-Molecule Modulators of Toll-like Receptors. , 2020, Accounts of chemical research.

[2]  T. Seya,et al.  Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy , 2020, Expert opinion on biological therapy.

[3]  yang-xin fu,et al.  Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling , 2020, Nature Immunology.

[4]  J. Rehwinkel,et al.  RIG-I-like receptors: their regulation and roles in RNA sensing , 2020, Nature Reviews Immunology.

[5]  D. Weiner,et al.  CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[7]  H. Rothan,et al.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.

[8]  M. Satyamitra,et al.  CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice , 2020, Scientific Reports.

[9]  G. Kroemer,et al.  Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses , 2020, Cell stress.

[10]  K. Wada,et al.  Cytosolic domain of SIDT2 carries an arginine-rich motif that binds to RNA/DNA and is important for the direct transport of nucleic acids into lysosomes , 2020, Autophagy.

[11]  M. Campone,et al.  STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment , 2020, Nature Communications.

[12]  P. Sharma,et al.  Dissecting the mechanisms of immune checkpoint therapy , 2020, Nature Reviews Immunology.

[13]  J. Locasale,et al.  Metabolism in the tumor microenvironment: insights from single-cell analysis , 2020, Oncoimmunology.

[14]  L. Galluzzi,et al.  PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models , 2020, Oncoimmunology.

[15]  Jingting Jiang,et al.  Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment , 2020, Oncoimmunology.

[16]  T. D. de Gruijl,et al.  In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma , 2019, Oncoimmunology.

[17]  J. Mazières,et al.  The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study , 2019, Oncoimmunology.

[18]  D. Stetson,et al.  Human DNA-PK activates a STING-independent DNA sensing pathway , 2019, Science Immunology.

[19]  S. Pascarella,et al.  COVID-19 Outbreak: An Overview , 2020, Chemotherapy.

[20]  A. Berghoff,et al.  New emerging targets in cancer immunotherapy: CD27 (TNFRSF7) , 2020, ESMO Open.

[21]  R. Zhou,et al.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases , 2019, Nature Reviews Immunology.

[22]  L. Galluzzi,et al.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment , 2019, Nature Immunology.

[23]  Yan‐Mei Li,et al.  Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy , 2019, Medicinal research reviews.

[24]  Bevacizumab , 2019, Reactions Weekly.

[25]  T. Zheng,et al.  STING: a master regulator in the cancer-immunity cycle , 2019, Molecular Cancer.

[26]  Y. Ko,et al.  Metastatic colorectal cancer: therapeutic options for treating refractory disease. , 2019, Current oncology.

[27]  G. Zeng,et al.  cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. , 2019, The Journal of clinical investigation.

[28]  N. Hirokawa,et al.  Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury. , 2019, Cell reports.

[29]  K. Valerie,et al.  STING activation in cancer immunotherapy , 2019, Theranostics.

[30]  S. Ansell.  Pembrolizumab: living up to expectations. , 2019, Blood.

[31]  U. Pastorino,et al.  Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients , 2019, Scientific Reports.

[32]  M. van den Broek,et al.  Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity. , 2019, Cell reports.

[33]  Kirsty Minton.  Regulation of endosomal TLRs , 2019, Nature Reviews Immunology.

[34]  L. Galluzzi,et al.  Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles , 2019, Nature Reviews Drug Discovery.

[35]  Joo Hoon Kim,et al.  STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. , 2019, The Journal of clinical investigation.

[36]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[37]  L. Galluzzi,et al.  Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients , 2019, Oncoimmunology.

[38]  E. Yusko,et al.  The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients , 2019, Oncoimmunology.

[39]  L. Galluzzi,et al.  Apoptotic caspases cut down the immunogenicity of radiation , 2019, Oncoimmunology.

[40]  Eric Deutsch,et al.  Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. , 2019, The Lancet. Oncology.

[41]  C. Van Waes,et al.  Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. , 2019, Oral oncology.

[42]  K. Fitzgerald,et al.  DNA sensing by the cGAS–STING pathway in health and disease , 2019, Nature Reviews Genetics.

[43]  A. Harris,et al.  BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors , 2018, Nature Communications.

[44]  K. Harrington,et al.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) , 2019, Journal of Immunotherapy for Cancer.

[45]  J. Luke,et al.  STING pathway agonism as a cancer therapeutic , 2019, Immunological reviews.

[46]  M. Hao,et al.  Abstract 4456: Discovery of E7766: A representative of a novel class of macrocycle-bridged STING agonists (MBSAs) with superior potency and pan-genotypic activity , 2019, Cancer Chemistry.

[47]  N. Wages,et al.  A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients , 2019, Journal of Immunotherapy for Cancer.

[48]  Jian Zhang,et al.  A novel mutation panel for predicting etoposide resistance in small-cell lung cancer , 2019, Drug design, development and therapy.

[49]  S. Tait,et al.  Mitochondria and pathogen immunity: from killer to firestarter , 2019, The EMBO journal.

[50]  D. Green,et al.  Autophagy-Independent Functions of the Autophagy Machinery , 2019, Cell.

[51]  M. Hurwitz,et al.  A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. , 2019, Cancer discovery.

[52]  C. Gomez-Fernandez,et al.  The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial , 2019, Front. Immunol..

[53]  R. Dummer,et al.  Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. , 2019, Journal of Clinical Oncology.

[54]  M. Gale,et al.  Interleukin-1β Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STING. , 2019, Molecular cell.

[55]  I. Melero,et al.  Immunotherapeutic effects of intratumoral nanoplexed poly I:C , 2019, Journal of Immunotherapy for Cancer.

[56]  L. Galluzzi,et al.  Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. , 2019, Trends in cell biology.

[57]  Leonie Unterholzner,et al.  cGAS-independent STING activation in response to DNA damage , 2019, Molecular & cellular oncology.

[58]  B. Shi,et al.  Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells , 2019, Front. Oncol..

[59]  M. Merad,et al.  Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.

[60]  S. Rabkin,et al.  Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma , 2019, Oncoimmunology.

[61]  Zhengfan Jiang,et al.  Apoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and IRF3. , 2019, Molecular cell.

[62]  A. Patrikidou,et al.  Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients , 2019, Cancers.

[63]  P. Benaroch,et al.  TLR3 Activation of Intratumoral CD103+ Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity , 2019, Front. Immunol..

[64]  K. Song,et al.  Insights into the dynamic nature of the dsRNA-bound TLR3 complex , 2019, Scientific Reports.

[65]  G. Schackert,et al.  Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis , 2019, Scientific Reports.

[66]  K. Chok,et al.  Colorectal liver metastases: An update on multidisciplinary approach , 2019, World journal of hepatology.

[67]  A. Melcher,et al.  ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment , 2019, Clinical Cancer Research.

[68]  A. Ashworth,et al.  PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer , 2019, The Journal of clinical investigation.

[69]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[70]  Christopher A. Miller,et al.  Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma , 2019, Oncoimmunology.

[71]  R. Amaria,et al.  Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials , 2019, Therapeutic advances in medical oncology.

[72]  E. Rozeman,et al.  Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy , 2018, Oncoimmunology.

[73]  M. Sperandio,et al.  Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells , 2018, Oncoimmunology.

[74]  Yayi Hou,et al.  Toll‐like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3‐UNC93B1‐IFN‐β signaling axis in paclitaxel‐resistant colon cancer , 2018, Journal of cellular physiology.

[75]  S. Shapira,et al.  Negative Regulation of Cytosolic Sensing of DNA , 2018, International Review of Cell and Molecular Biology.

[76]  L. Kuryk,et al.  Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model , 2018, Oncoimmunology.

[77]  S. Hugues,et al.  Warming up the tumor microenvironment in order to enhance immunogenicity , 2018, Oncoimmunology.

[78]  H. Funabiki,et al.  The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death , 2019, Cell.

[79]  J. Idoyaga,et al.  The versatile plasmacytoid dendritic cell: Function, heterogeneity, and plasticity. , 2019, International review of cell and molecular biology.

[80]  J. Banchereau,et al.  Interplay between dendritic cells and cancer cells. , 2019, International review of cell and molecular biology.

[81]  N. Bhardwaj,et al.  Dendritic cell subsets and locations. , 2019, International review of cell and molecular biology.

[82]  Fiorella Kotsias,et al.  Antigen processing and presentation. , 2019, International review of cell and molecular biology.

[83]  K. Macleod,et al.  Autophagy and cancer cell metabolism. , 2019, International review of cell and molecular biology.

[84]  K. Radford,et al.  The role of dendritic cells in cancer. , 2019, International review of cell and molecular biology.

[85]  A. Garg,et al.  Type I interferons and dendritic cells in cancer immunotherapy. , 2019, International review of cell and molecular biology.

[86]  E. Roselli,et al.  TLR 3 Activation of Intratumoral CD 103 Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity , 2019 .

[87]  Alan G. Goodman,et al.  The Role of Nucleic Acid Sensing in Controlling Microbial and Autoimmune Disorders. , 2019, International review of cell and molecular biology.

[88]  Jianguo He,et al.  Nucleic Acid Sensing in Invertebrate Antiviral Immunity. , 2019, International review of cell and molecular biology.

[89]  A. Alice,et al.  Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity. , 2019, International review of cell and molecular biology.

[90]  L. Galluzzi,et al.  Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity. , 2019, International review of cell and molecular biology.

[91]  N. Khodarev.  Intracellular RNA Sensing in Mammalian Cells: Role in Stress Response and Cancer Therapies. , 2019, International review of cell and molecular biology.

[92]  M. Vesely,et al.  Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. , 2019, International review of cell and molecular biology.

[93]  A. Han,et al.  Cancer Immunosurveillance by T Cells. , 2019, International review of cell and molecular biology.

[94]  Alyssa R. Richman,et al.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial , 2018, Nature.

[95]  M. Smyth,et al.  Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.

[96]  G. Freeman,et al.  PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer , 2018, Cell reports.

[97]  T. Petro,et al.  IFN-γ synergism with poly I:C reduces growth of murine and human cancer cells with simultaneous changes in cell cycle and immune checkpoint proteins. , 2018, Cancer letters.

[98]  S. Eisenbarth,et al.  Dendritic cell subsets in T cell programming: location dictates function , 2018, Nature Reviews Immunology.

[99]  Kristy M Ainslie,et al.  A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. , 2018, JCI insight.

[100]  W. Chan,et al.  CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates , 2018, The Journal of Immunology.

[101]  Joseph P. Romano,et al.  Design of amidobenzimidazole STING receptor agonists with systemic activity , 2018, Nature.

[102]  T. MacDonald,et al.  PDCT-03. A PHASE II TRIAL OF POLY-ICLC IN THE MANAGEMENT OF RECURRENT OR PROGRESSIVE PEDIATRIC LOW GRADE GLIOMAS. RESULTS FOR THE NEUROFIBROMATOSIS 1 GROUP. (NCT01188096) , 2018, Neuro-Oncology.

[103]  G. Tseng,et al.  Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles , 2018, Oncogene.

[104]  L. Zitvogel,et al.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy , 2018, Oncoimmunology.

[105]  L. Galluzzi,et al.  Linking cellular stress responses to systemic homeostasis , 2018, Nature Reviews Molecular Cell Biology.

[106]  K. Dheda,et al.  An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells , 2018, Cancer Immunology, Immunotherapy.

[107]  K. Harrington,et al.  Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  S. Formenti,et al.  Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation , 2018, Advances in radiation oncology.

[109]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[110]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[111]  E. Gilboa,et al.  An RNA toolbox for cancer immunotherapy , 2018, Nature Reviews Drug Discovery.

[112]  L. Zitvogel,et al.  Trial watch: Peptide-based vaccines in anticancer therapy , 2018, Oncoimmunology.

[113]  L. Galluzzi,et al.  Cytosolic DNA Sensing in Organismal Tumor Control. , 2018, Cancer Cell.

[114]  A. Bowie,et al.  Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage , 2018, Molecular cell.

[115]  A. Salazar,et al.  Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma , 2018, Oncoimmunology.

[116]  R. Ferris,et al.  T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response , 2018, Oncoimmunology.

[117]  H. Cai,et al.  Parkin and PINK1 mitigate STING-induced inflammation , 2018, Nature.

[118]  F. Sánchez‐Madrid,et al.  Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts , 2018, Nature Communications.

[119]  M. Maiuri,et al.  Aspirin—another caloric-restriction mimetic , 2018, Autophagy.

[120]  J. Adams,et al.  Abstract 5554: Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity , 2018, Clinical Research (Excluding Clinical Trials).

[121]  T. Gilmore,et al.  Evolutionary Origins of Toll-like Receptor Signaling , 2018, Molecular biology and evolution.

[122]  W. Loging,et al.  Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial , 2018, Clinical Cancer Research.

[123]  H. Shime,et al.  Vaccine immunotherapy with ARNAX induces tumor‐specific memory T cells and durable anti‐tumor immunity in mouse models , 2018, Cancer science.

[124]  B. Ueberheide,et al.  Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs , 2018, Cancer Immunology Research.

[125]  K. Janssen,et al.  Cell-type specific MyD88 signaling is required for intestinal tumor initiation and progression to malignancy , 2018, Oncoimmunology.

[126]  M. Maiuri,et al.  Aspirin induces autophagy via inhibition of the acetyltransferase EP300 , 2018, Oncotarget.

[127]  G. Mills,et al.  PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. , 2018, Cancer research.

[128]  N. Zarghami,et al.  An overview on Vadimezan (DMXAA): The vascular disrupting agent , 2018, Chemical biology & drug design.

[129]  J. Emile,et al.  Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab , 2018, Oncoimmunology.

[130]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[131]  L. Galluzzi,et al.  SnapShot: CGAS-STING Signaling , 2018, Cell.

[132]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[133]  R. Hannan,et al.  Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy , 2018, Oncoimmunology.

[134]  A. Giobbie-Hurder,et al.  Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma , 2018, Oncoimmunology.

[135]  T. Seya,et al.  Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy , 2018, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[136]  A. Rogel,et al.  PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity , 2018, Clinical Cancer Research.

[137]  Ernest Y Lee,et al.  Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors , 2018, Scientific Reports.

[138]  Jan Tavernier,et al.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment , 2018, Oncoimmunology.

[139]  Weiwei Wang,et al.  Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma. , 2018, Biomaterials.

[140]  Nektarios Tavernarakis,et al.  Aspirin Recapitulates Features of Caloric Restriction , 2018, Cell reports.

[141]  K. Rogers,et al.  BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis , 2018, Science.

[142]  L. Galluzzi,et al.  The autophagic network and cancer , 2018, Nature Cell Biology.

[143]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[144]  C. Rice,et al.  Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown , 2018, Cell.

[145]  H. Harada,et al.  Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy , 2018, Oncotarget.

[146]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[147]  M. Donia,et al.  Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab , 2018, Oncoimmunology.

[148]  P. Agarwal,et al.  Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors , 2017, Oncoimmunology.

[149]  L. Galluzzi,et al.  Mitochondrial metabolism and cancer , 2017, Cell Research.

[150]  Samuel F. Bakhoum,et al.  Chromosomal instability drives metastasis through a cytosolic DNA response , 2017, Nature.

[151]  Gerardo Botti,et al.  PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab , 2017, Oncoimmunology.

[152]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[153]  Young J. Kim.  STINGing the Tumor's immune evasion mechanism , 2015, Oncoimmunology.

[154]  A. Borrie,et al.  T Lymphocyte-Based Cancer Immunotherapeutics. , 2018, International review of cell and molecular biology.

[155]  T. P. Neufeld,et al.  Membrane Trafficking in Autophagy. , 2018, International review of cell and molecular biology.

[156]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[157]  Jonathan J. West,et al.  Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment , 2017, Cancer cell.

[158]  B. Ueberheide,et al.  STING Senses Microbial Viability to Orchestrate Stress-Mediated Autophagy of the Endoplasmic Reticulum , 2017, Cell.

[159]  P. Agostinis,et al.  Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses , 2017, Immunological reviews.

[160]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[161]  E. Tagliabue,et al.  Exploiting poly(I:C) to induce cancer cell apoptosis , 2017, Cancer biology & therapy.

[162]  L. Emens.  Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.

[163]  S. Paczesny,et al.  Editorial: Danger Signals Triggering Immune Response and Inflammation , 2017, Front. Immunol..

[164]  F. Pan,et al.  The regulation of immune tolerance by FOXP3 , 2017, Nature Reviews Immunology.

[165]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[166]  Martin A. M. Reijns,et al.  cGAS surveillance of micronuclei links genome instability to innate immunity , 2017, Nature.

[167]  A. Trautmann,et al.  The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression , 2017, Oncoimmunology.

[168]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[169]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[170]  C. Ager,et al.  Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity , 2017, Cancer Immunology Research.

[171]  Dennis E Discher,et al.  Mitotic progression following DNA damage enables pattern recognition within micronuclei , 2017, Nature.

[172]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[173]  A. Enk,et al.  Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe) , 2017, Oncoimmunology.

[174]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[175]  L. Galluzzi,et al.  DNA Damage in Stem Cells. , 2017, Molecular cell.

[176]  J. Nemunaitis,et al.  Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[178]  I. Haga,et al.  IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes , 2017, Nature Communications.

[179]  L. K. Sørensen,et al.  IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP , 2017, Nature Communications.

[180]  P. Cohen,et al.  Identification of TBK1 complexes required for the phosphorylation of IRF3 and the production of interferon β , 2017, The Biochemical journal.

[181]  Daniel S. Chertow,et al.  Necroptosis: Mechanisms and Relevance to Disease , 2017 .

[182]  S. Oliveira,et al.  TLR7 and TLR3 Sense Brucella abortus RNA to Induce Proinflammatory Cytokine Production but They Are Dispensable for Host Control of Infection , 2017, Front. Immunol..

[183]  Akshay Jain,et al.  Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery. , 2017, Molecular pharmaceutics.

[184]  D. Green,et al.  Necroptosis in development, inflammation and disease , 2016, Nature Reviews Molecular Cell Biology.

[185]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[186]  Jason B. Williams,et al.  Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. , 2017, Advances in experimental medicine and biology.

[187]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  T. Gajewski,et al.  Innate immune signaling and regulation in cancer immunotherapy , 2016, Cell Research.

[189]  Zhijian J. Chen,et al.  Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing , 2016, Nature Immunology.

[190]  L. Zitvogel,et al.  The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ , 2016, Oncoimmunology.

[191]  G. Hartmann,et al.  Discriminating self from non-self in nucleic acid sensing , 2016, Nature Reviews Immunology.

[192]  M. Karin,et al.  Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment , 2016, Cell.

[193]  L. Zitvogel,et al.  Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. , 2016, Cancer research.

[194]  P. Tan,et al.  The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells. , 2016, Immunity.

[195]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[196]  L. Zitvogel,et al.  Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1 , 2016, Oncoimmunology.

[197]  Peng Dai,et al.  Activation of innate antiviral immune response via double-stranded RNA-dependent RLR receptor-mediated necroptosis , 2016, Scientific Reports.

[198]  L. Galluzzi,et al.  Caspases Connect Cell-Death Signaling to Organismal Homeostasis. , 2016, Immunity.

[199]  T. Seya,et al.  Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia , 2016, Oncoimmunology.

[200]  Gang Wu,et al.  Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity , 2016, Oncoimmunology.

[201]  M. Addepalli,et al.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.

[202]  Napoleone Ferrara,et al.  Ten years of anti-vascular endothelial growth factor therapy , 2016, Nature Reviews Drug Discovery.

[203]  P. Vandenabeele,et al.  Regulated necrosis: disease relevance and therapeutic opportunities , 2016, Nature reviews. Drug discovery.

[204]  G. Barber,et al.  Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. , 2016, Cell reports.

[205]  Si Ming Man,et al.  Converging roles of caspases in inflammasome activation, cell death and innate immunity , 2015, Nature Reviews Immunology.

[206]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[207]  G. Barber.  STING: infection, inflammation and cancer , 2015, Nature Reviews Immunology.

[208]  F. Martinon,et al.  STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity , 2015, Proceedings of the National Academy of Sciences.

[209]  L. Zitvogel,et al.  Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 , 2015, Science.

[210]  Michael R Hamblin,et al.  Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death , 2015, Front. Immunol..

[211]  Elizabeth E Gray,et al.  DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway , 2015, Science.

[212]  T. Gajewski,et al.  Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer , 2015, Clinical Cancer Research.

[213]  David Killock.  Haematological cancer: Resiquimod—a topical CTCL therapy , 2015, Nature Reviews Clinical Oncology.

[214]  L. Zitvogel,et al.  Autocrine signaling of type 1 interferons in successful anticancer chemotherapy , 2015, Oncoimmunology.

[215]  A. Hurley,et al.  Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers , 2015, Bone Marrow Transplantation.

[216]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[217]  L. Galluzzi,et al.  Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark , 2015, Oncoimmunology.

[218]  Bo-Kyung Kim,et al.  Tonsil-derived mesenchymal stromal cells produce CXCR2-binding chemokines and acquire follicular dendritic cell-like phenotypes under TLR3 stimulation. , 2015, Cytokine.

[219]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[220]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[221]  Zili Wang,et al.  STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice , 2015, Cancer Immunology, Immunotherapy.

[222]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[223]  S. Okada,et al.  PolyI:C–Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector–Mediated Tumor Elimination In Vivo , 2015, Cancer Immunology Research.

[224]  D. Pardoll,et al.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade , 2015, Science Translational Medicine.

[225]  T. Gajewski,et al.  Innate immune recognition of cancer. , 2015, Annual review of immunology.

[226]  J. Qin,et al.  TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis , 2015, BMC Cancer.

[227]  L. Whilding,et al.  ErbB-targeted CAR T-cell immunotherapy of cancer. , 2015, Immunotherapy.

[228]  A. Oxenius,et al.  Regulation of antiviral T cell responses by type I interferons , 2015, Nature Reviews Immunology.

[229]  P. Altevogt,et al.  Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment , 2015, Oncoimmunology.

[230]  H. Shime,et al.  Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo , 2015, Nature Communications.

[231]  W. Bishai,et al.  A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis , 2015, Nature Medicine.

[232]  D. Schrijvers,et al.  Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. , 2015, Pharmacology & therapeutics.

[233]  A. Filippini,et al.  Transfected Poly(I:C) Activates Different dsRNA Receptors, Leading to Apoptosis or Immunoadjuvant Response in Androgen-independent Prostate Cancer Cells* , 2015, The Journal of Biological Chemistry.

[234]  D. Chandra,et al.  Targeting STING pathways for the treatment of cancer , 2015, Oncoimmunology.

[235]  R. Means,et al.  Mitochondrial DNA Stress Primes the Antiviral Innate Immune Response , 2014, Nature.

[236]  T. Taniguchi,et al.  Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA , 2014, Cell.

[237]  Matthew E. Ritchie,et al.  Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production , 2014, Cell.

[238]  E. Janssen,et al.  STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells , 2014, The Journal of Immunology.

[239]  S. Rutz,et al.  The IL-20 subfamily of cytokines — from host defence to tissue homeostasis , 2014, Nature Reviews Immunology.

[240]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[241]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[242]  Si Ming Man,et al.  Cutting Edge: STING Mediates Protection against Colorectal Tumorigenesis by Governing the Magnitude of Intestinal Inflammation , 2014, The Journal of Immunology.

[243]  L. Zitvogel,et al.  CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. , 2014, Cancer cell.

[244]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[245]  Simon C Watkins,et al.  STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[246]  T. Mitchison,et al.  Hydrolysis of 2′3′-cGAMP by ENPP1 and design of non-hydrolyzable analogs , 2014, Nature chemical biology.

[247]  S. Bertholet,et al.  Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants , 2014, Proceedings of the National Academy of Sciences.

[248]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[249]  T. Decker,et al.  Listeria monocytogenes induces IFNβ expression through an IFI16‐, cGAS‐ and STING‐dependent pathway , 2014, The EMBO journal.

[250]  Jie Zhou,et al.  STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer , 2014, Cancer Immunology Research.

[251]  L. Zitvogel,et al.  Trial Watch , 2014, Oncoimmunology.

[252]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[253]  P. Mukherjee,et al.  MUC1: a multifaceted oncoprotein with a key role in cancer progression. , 2014, Trends in molecular medicine.

[254]  A. Salazar,et al.  Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial , 2014, Cancer Immunology Research.

[255]  K. Zeljic,et al.  Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. , 2014, Oral diseases.

[256]  G. Barber,et al.  Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-κB Activation through TBK1 , 2014, Journal of Virology.

[257]  L. Zitvogel,et al.  Trial Watch , 2014, Oncoimmunology.

[258]  L. Zitvogel,et al.  Trial Watch , 2004, Oncoimmunology.

[259]  J. Rohayem,et al.  Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100 , 2013, Clinical & developmental immunology.

[260]  Leonie Unterholzner.  The interferon response to intracellular DNA: why so many receptors? , 2013, Immunobiology.

[261]  J. Shim,et al.  IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women , 2013, Front. Immunol..

[262]  Yan Zhang,et al.  Tumor vascular disrupting agent 5,6‐dimethylxanthenone‐4‐acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase , 2013, Journal of thrombosis and haemostasis : JTH.

[263]  J. Bertin,et al.  Toll-like Receptor 3-mediated Necrosis via TRIF, RIP3, and MLKL* , 2013, The Journal of Biological Chemistry.

[264]  M. Tai,et al.  Toll-like receptor 3 expression inhibits cell invasion and migration and predicts a favorable prognosis in neuroblastoma. , 2013, Cancer letters.

[265]  P. Darcy,et al.  Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy , 2013, Oncoimmunology.

[266]  Christina Appin,et al.  Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class , 2013, Clinical Cancer Research.

[267]  V. Hornung,et al.  cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING , 2013, Nature.

[268]  R. Vance,et al.  The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. , 2013, Cell reports.

[269]  V. Hornung,et al.  Structural mechanism of cytosolic DNA sensing by cGAS , 2013, Nature.

[270]  A. Bowie,et al.  Immune sensing of DNA. , 2013, Immunity.

[271]  Roger A. Jones,et al.  Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase , 2013, Cell.

[272]  B. Monks,et al.  Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid , 2013, The Journal of Immunology.

[273]  P. Vandenabeele,et al.  Many faces of DAMPs in cancer therapy , 2013, Cell Death and Disease.

[274]  J. Lee,et al.  TLR3 agonists and proinflammatory antitumor activities , 2013, Expert opinion on therapeutic targets.

[275]  G. Barber,et al.  STING recognition of cytoplasmic DNA instigates cellular defense. , 2013, Molecular cell.

[276]  L. Galluzzi,et al.  Cisplatin resistance associated with PARP hyperactivation. , 2013, Cancer research.

[277]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[278]  Zhendong Zheng,et al.  Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma , 2013, Tumor Biology.

[279]  K. Ishii,et al.  DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking , 2013, Proceedings of the National Academy of Sciences.

[280]  John R. Young,et al.  A Critical Role for MAPK Signalling Pathways in the Transcriptional Regulation of Toll Like Receptors , 2013, PloS one.

[281]  Divyendu Singh,et al.  The Human Antimicrobial Peptide LL-37, but Not the Mouse Ortholog, mCRAMP, Can Stimulate Signaling by Poly(I:C) through a FPRL1-dependent Pathway* , 2013, The Journal of Biological Chemistry.

[282]  Y. Modis,et al.  Crystal structure of the dimeric coiled-coil domain of the cytosolic nucleic acid sensor LRRFIP1. , 2012, Journal of structural biology.

[283]  H. Ren,et al.  DNA-PK is a DNA sensor for IRF-3-dependent innate immunity , 2012, eLife.

[284]  N. Copeland,et al.  Toll-Like Receptor 3 Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients , 2012, Journal of the National Cancer Institute.

[285]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[286]  P. Kalinski,et al.  Lymphocyte-polarized DC1s , 2012, Oncoimmunology.

[287]  Sangdun Choi,et al.  Therapeutic Applications of Nucleic Acids and Their Analogues in Toll-like Receptor Signaling , 2012, Molecules.

[288]  S. Vogel,et al.  5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential* , 2012, The Journal of Biological Chemistry.

[289]  Ming Li,et al.  An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.

[290]  L. Zitvogel,et al.  Trial watch , 2012, Oncoimmunology.

[291]  Daigo Hashimoto,et al.  Deciphering the transcriptional network of the DC lineage , 2012, Nature Immunology.

[292]  R. Wolff,et al.  Toll‐like receptor genes and their association with colon and rectal cancer development and prognosis , 2012, International journal of cancer.

[293]  D. Strayer,et al.  A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome , 2012, PloS one.

[294]  G. Simon,et al.  Antiangiogenic agents in the management of non-small cell lung cancer , 2012, Cancer biology & therapy.

[295]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[296]  Hongbing Shen,et al.  Host immune gene polymorphisms were associated with the prognosis of non‐small‐cell lung cancer in Chinese , 2012, International journal of cancer.

[297]  L. Zitvogel,et al.  Trial watch , 2005, Oncoimmunology.

[298]  B. Baguley,et al.  Immunomodulatory Actions of Xanthenone Anticancer Agents , 1997, BioDrugs.

[299]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[300]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[301]  Y. Horio,et al.  The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. , 2011, Japanese journal of clinical oncology.

[302]  L. Galluzzi,et al.  Illicit survival of cancer cells during polyploidization and depolyploidization , 2011, Cell Death and Differentiation.

[303]  G. Barber,et al.  IRF7: activation, regulation, modification and function , 2011, Genes and Immunity.

[304]  P. Kantoff,et al.  Immunotherapy for the treatment of prostate cancer , 2011, Nature Reviews Clinical Oncology.

[305]  Yoshihiro Hayakawa,et al.  STING is a direct innate immune sensor of cyclic-di-GMP , 2011, Nature.

[306]  G. Scagliotti,et al.  Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[307]  M. Ross,et al.  Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[308]  J. Sauer,et al.  Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity , 2011, Proceedings of the National Academy of Sciences.

[309]  J. Hampe,et al.  TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. , 2011, European journal of cancer.

[310]  Lin Ge,et al.  Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women , 2011, Chinese journal of cancer.

[311]  S. Levine,et al.  Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. , 2011, Cytokine & growth factor reviews.

[312]  R. Weichselbaum,et al.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. , 2011, Cancer research.

[313]  L. Zitvogel,et al.  TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. , 2011, Cancer research.

[314]  D. Venzon,et al.  TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection , 2011, The Journal of Immunology.

[315]  Tsukasa Seya,et al.  Raftlin Is Involved in the Nucleocapture Complex to Induce Poly(I:C)-mediated TLR3 Activation* , 2011, The Journal of Biological Chemistry.

[316]  M. Rämet,et al.  The Drosophila Toll Signaling Pathway , 2011, The Journal of Immunology.

[317]  R. Schiff,et al.  HER 2: Biology, Detection, and Clinical Implications , 2011 .

[318]  Carolina Gutierrez,et al.  HER2: biology, detection, and clinical implications. , 2011, Archives of pathology & laboratory medicine.

[319]  K. Sakamoto,et al.  The Role of the Transcription Factor CREB in Immune Function , 2010, The Journal of Immunology.

[320]  M. McKeage,et al.  Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. , 2010, Journal of thoracic disease.

[321]  Sky W. Brubaker,et al.  The N-Ethyl-N-Nitrosourea-Induced Goldenticket Mouse Mutant Reveals an Essential Function of Sting in the In Vivo Interferon Response to Listeria monocytogenes and Cyclic Dinucleotides , 2010, Infection and Immunity.

[322]  A. Psyrri,et al.  Targeted therapies: Molecular selection for 'smart' study design in lung cancer , 2010, Nature Reviews Clinical Oncology.

[323]  B. Baguley,et al.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA) , 2010, Expert opinion on investigational drugs.

[324]  Christophe Caux,et al.  TLR3 and Rig-Like Receptor on Myeloid Dendritic Cells and Rig-Like Receptor on Human NK Cells Are Both Mandatory for Production of IFN-γ in Response to Double-Stranded RNA , 2010, The Journal of Immunology.

[325]  James Ze Wang,et al.  Stereotactic body radiation therapy: a novel treatment modality , 2010, Nature Reviews Clinical Oncology.

[326]  C. Drake.  Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.

[327]  P. Rod Dunbar,et al.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens , 2010, The Journal of experimental medicine.

[328]  Pengyuan Yang,et al.  The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a β-catenin-dependent pathway , 2010, Nature Immunology.

[329]  P. Kloetzel,et al.  Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells , 2010, The Journal of experimental medicine.

[330]  Andrew E. Parker,et al.  Targeting Toll-like receptors: emerging therapeutics? , 2010, Nature Reviews Drug Discovery.

[331]  B. Beutler,et al.  Intracellular toll-like receptors. , 2010, Immunity.

[332]  J. Berek,et al.  TLR3 agonists as immunotherapeutic agents. , 2010, Immunotherapy.

[333]  L. Zitvogel,et al.  Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. , 2010, Cancer research.

[334]  S. Adams.  Toll-like receptor agonists in cancer therapy. , 2009, Immunotherapy.

[335]  Himanshu Kumar,et al.  Toll-like receptors and innate immunity. , 2009, Biochemical and biophysical research communications.

[336]  G. Barber,et al.  STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity , 2009, Nature.

[337]  K. Kawa,et al.  Epstein-Barr virus (EBV)–encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3 , 2009, The Journal of experimental medicine.

[338]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[339]  Joseph K. Pickrell,et al.  Evolutionary Dynamics of Human Toll-Like Receptors and Their Different Contributions to Host Defense , 2009, PLoS genetics.

[340]  G. Acton,et al.  Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. , 2009, Investigative ophthalmology & visual science.

[341]  B. Jasani,et al.  Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. , 2009, Vaccine.

[342]  B. Beutler.  TLRs and innate immunity. , 2009, Blood.

[343]  M. Mason,et al.  A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. , 2009, Vaccine.

[344]  T. Seya,et al.  The Clathrin-Mediated Endocytic Pathway Participates in dsRNA-Induced IFN-β Production1 , 2008, The Journal of Immunology.

[345]  R. Gallo,et al.  Toll-like receptors in skin infections and inflammatory diseases. , 2008, Infectious disorders drug targets.

[346]  G. Barber,et al.  STING an Endoplasmic Reticulum Adaptor that Facilitates Innate Immune Signaling , 2008, Nature.

[347]  S. H. Kim,et al.  Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases , 2008, British Journal of Cancer.

[348]  Ruth R. Montgomery,et al.  Dysregulation of TLR3 Impairs the Innate Immune Response to West Nile Virus in the Elderly , 2008, Journal of Virology.

[349]  杉山 孝弘.  Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7 , 2008 .

[350]  B. Lemaître,et al.  Toll-like receptors — taking an evolutionary approach , 2008, Nature Reviews Genetics.

[351]  M. McKeage.  The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer , 2008, Expert opinion on investigational drugs.

[352]  Rudi Beyaert,et al.  Sensing of Viral Infection and Activation of Innate Immunity by Toll-Like Receptor 3 , 2008, Clinical Microbiology Reviews.

[353]  C. Slingluff,et al.  Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting , 2007, Clinical Cancer Research.

[354]  P. Borrow,et al.  Polyinosinic Acid Is a Ligand for Toll-like Receptor 3* , 2007, Journal of Biological Chemistry.

[355]  Philippe Dessen,et al.  A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. , 2007, Cancer research.

[356]  S. Akira,et al.  Toll-like Receptors and Type I Interferons* , 2007, Journal of Biological Chemistry.

[357]  B. Boehm,et al.  Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells. , 2007, Cellular immunology.

[358]  A. Bowie,et al.  The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling , 2007, Nature Reviews Immunology.

[359]  B. Baguley,et al.  Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours , 2007, Cancer Chemotherapy and Pharmacology.

[360]  H. Carter,et al.  The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. , 2006, The Journal of urology.

[361]  N. Gay,et al.  Toll-like receptors as molecular switches , 2006, Nature Reviews Immunology.

[362]  Christian Ludwig,et al.  Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. , 2006, Neoplasia.

[363]  S. Akira,et al.  TLR signaling , 2006, Cell Death and Differentiation.

[364]  A. Kaur,et al.  The evolution of vertebrate Toll-like receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[365]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[366]  V. Cerundolo,et al.  Viral Immunity: Cross-Priming with the Help of TLR3 , 2005, Current Biology.

[367]  M. Offermann,et al.  Apoptosis Induced by the Toll-Like Receptor Adaptor TRIF Is Dependent on Its Receptor Interacting Protein Homotypic Interaction Motif1 , 2005, The Journal of Immunology.

[368]  G. Sen,et al.  Transcriptional signaling by double-stranded RNA: role of TLR3. , 2005, Cytokine & growth factor reviews.

[369]  S. Sakamoto,et al.  Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling , 2004, Nature Structural &Molecular Biology.

[370]  M. Horsman,et al.  Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid , 2004, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[371]  Sam S. Chang.  Overview of prostate-specific membrane antigen. , 2004, Reviews in urology.

[372]  M. Philpott,et al.  Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid , 2004, Cancer Chemotherapy and Pharmacology.

[373]  J. Cummings,et al.  Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours , 2004, Cancer Chemotherapy and Pharmacology.

[374]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[375]  L. Gumbrell,et al.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent , 2003, British Journal of Cancer.

[376]  G. Rustin,et al.  5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study , 2003, British Journal of Cancer.

[377]  B. Baguley.  Antivascular therapy of cancer: DMXAA. , 2003, The Lancet. Oncology.

[378]  H. Griesser,et al.  Immobilization and surface characterization of NeutrAvidin biotin-binding protein on different hydrogel interlayers. , 2003, Journal of colloid and interface science.

[379]  G. Sen,et al.  Double-stranded RNA Signaling by Toll-like Receptor 3 Requires Specific Tyrosine Residues in Its Cytoplasmic Domain* , 2003, The Journal of Biological Chemistry.

[380]  Govinda Rao,et al.  IRF3 mediates a TLR3/TLR4-specific antiviral gene program. , 2002, Immunity.

[381]  C. Kieda,et al.  Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid , 2002, British Journal of Cancer.

[382]  S. Ascarateil,et al.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines , 2002, Expert review of vaccines.

[383]  W. Wilson,et al.  Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) , 2002, Cancer Chemotherapy and Pharmacology.

[384]  G. Krissansen,et al.  Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. , 2001, Cancer research.

[385]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[386]  R. Verdijk,et al.  Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. , 1999, Journal of immunology.

[387]  B. Palmer,et al.  Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid , 1999, British Journal of Cancer.

[388]  B. Baguley,et al.  Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. , 1999, Cancer research.

[389]  W. Wilson,et al.  Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. , 1998, International journal of radiation oncology, biology, physics.

[390]  B. Palmer,et al.  Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. , 1998, British Journal of Cancer.

[391]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[392]  N. Holford,et al.  Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid , 1997, Cancer Chemotherapy and Pharmacology.

[393]  B. Lemaître,et al.  The Dorsoventral Regulatory Gene Cassette spätzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults , 1996, Cell.

[394]  R. Pedley,et al.  Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. , 1996, Cancer research.

[395]  N. Davidson.  Paclitaxel , 1995, The Lancet.

[396]  J. Double,et al.  Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. , 1995, British Journal of Cancer.

[397]  D. Strayer,et al.  Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen , 1995 .

[398]  F. Trautinger,et al.  Long-Term Adjuvant Therapy of High-Risk Malignant Melanoma with Interferon α2b , 1990 .

[399]  J. Gavin,et al.  Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. , 1990, British Journal of Cancer.

[400]  F. Trautinger,et al.  Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b. , 1990, The Journal of investigative dermatology.

[401]  J. Abrams,et al.  Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015). , 1987, European journal of cancer & clinical oncology.

[402]  D. Kerr,et al.  Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). , 1986, Cancer research.

[403]  K. Paull,et al.  Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. , 1986, Cancer treatment reports.

[404]  D. Strayer,et al.  Clinical studies with ampligen (mismatched double-stranded RNA). , 1985, Journal of biological response modifiers.

[405]  J. Youn,et al.  A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients. , 1985, Journal of biological response modifiers.

[406]  A. Spira,et al.  Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. , 1984, British medical journal.

[407]  A. Spira,et al.  ADJUVANT TREATMENT WITH POLYADENYLIC-POLYURIDYLIC ACID (POLYA.POLYU) IN OPERABLE BREAST CANCER , 1980, The Lancet.

[408]  Levine As,et al.  Phase I-II trials of poly IC stabilized with poly-L-lysine. , 1978 .

[409]  A. Levine,et al.  Phase I-II trials of poly IC stabilized with poly-L-lysine. , 1978, Cancer treatment reports.

[410]  V. Devita,et al.  A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. , 1976, Journal of the National Cancer Institute.

[411]  M. Iadarola,et al.  A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. , 1975, The Journal of infectious diseases.

[412]  M. D. Eaton,et al.  Further Observations on the Inhibitory Effect of Myxoviruses on a Transplantable Murine Leukemia 1 , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[413]  M. Hilleman,et al.  Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. , 1967, Proceedings of the National Academy of Sciences of the United States of America.